GenoTech Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Public

  • Employees
  • 28

Employees

  • Stock Symbol
  • 066830

Stock Symbol

  • Share Price
  • $0.96
  • (As of Wednesday Closing)

GenoTech General Information

Description

Genotech Corp is engaged in manufacturing basic pharmaceutical substances and biological agents.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 26-69, Gajeongbuk-ro
  • Daejeon, Yuseong-gu 305-343
  • South Korea
+82
Primary Industry
Biotechnology
Stock Exchange
KRX
Vertical(s)
Corporate Office
  • 26-69, Gajeongbuk-ro
  • Daejeon, Yuseong-gu 305-343
  • South Korea
+82

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GenoTech Stock Performance

As of 19-Mar-2025, GenoTech’s stock price is $0.96. Its current market cap is $5.45M.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.96 $0.97 $0.75 - $1.40 $5.45M 154.63 -$0.10

GenoTech Financials Summary

As of 31-Dec-2024, GenoTech has a trailing 12-month revenue of $1.8M.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 1,185 1,185 3,471 9,893
Revenue 1,798 1,798 2,104 4,029
EBITDA (447) (447) (109) 1,585
Net Income (557) (557) (201) 1,358
Total Assets 7,811 7,811 9,493 10,478
Total Debt 0 0 0 565
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GenoTech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GenoTech‘s full profile, request access.

Request a free trial

GenoTech Patents

GenoTech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4159851-A1 Dna polymerase variant with improved discrimination of genetic variants Pending 29-May-2020
US-20230304082-A1 Dna polymerase variant with improved discrimination of genetic variants Pending 29-May-2020
EP-4159851-A4 Dna polymerase variant with improved discrimination of genetic variants Pending 29-May-2020
AU-2020401936-A1 Pcr method and pcr kit for increasing allelic discrimination Active 11-Dec-2019
US-20230046513-A1 Pcr method and pcr kit for increasing allelic discrimination Pending 11-Dec-2019 C12Q1/686
To view GenoTech’s complete patent history, request access »

GenoTech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GenoTech FAQs

  • When was GenoTech founded?

    GenoTech was founded in 1997.

  • Where is GenoTech headquartered?

    GenoTech is headquartered in Daejeon, South Korea.

  • What is the size of GenoTech?

    GenoTech has 28 total employees.

  • What industry is GenoTech in?

    GenoTech’s primary industry is Biotechnology.

  • Is GenoTech a private or public company?

    GenoTech is a Public company.

  • What is GenoTech’s stock symbol?

    The ticker symbol for GenoTech is 066830.

  • What is the current stock price of GenoTech?

    As of 19-Mar-2025 the stock price of GenoTech is $0.96.

  • What is the current market cap of GenoTech?

    The current market capitalization of GenoTech is $5.45M.

  • What is GenoTech’s current revenue?

    The trailing twelve month revenue for GenoTech is $1.8M.

  • What is GenoTech’s annual earnings per share (EPS)?

    GenoTech’s EPS for 12 months was -$0.10.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »